4 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- VFemale Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Skin and Connective Tissue Diseases, Urination Disorders, Urogenital Diseases, Urological Manifestations, autoimmune disease, connective tissue disorder, glomerulonephritis, immune system disorder, kidney disorder, lupus nephritis, nephritis, proteinuria, systemic lupus erythematosus, urinary system disorderRecruitingPhase 22026-10-01NCT05268289
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HSBacterial Infections and Mycoses, Infections, Skin and Connective Tissue Diseases, Suppuration, bacterial infectious disease, hidradenitis, hidradenitis suppurativa, skin disease caused by bacterial infection, skin disorder, skin disorder caused by infection, sweat gland disorderRecruitingPhase 32026-09-28NCT07665437
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)Bacterial Infections and Mycoses, Infections, Skin and Connective Tissue Diseases, Suppuration, bacterial infectious disease, dermatitis, hidradenitis, hidradenitis suppurativa, skin disease caused by bacterial infection, skin disorder, skin disorder caused by infection, sweat gland disorderActive, not recruitingPhase 32026-08-20NCT06799000
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGNFemale Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Urination Disorders, Urogenital Diseases, Urological Manifestations, proteinuria, urinary system disorderRecruitingPhase 32026-07-13NCT05755386